Souhaitez-vous accéder aux communiqués récents ?

Data Presented at EUROPACE 2017 Reinforce Cost and Outcome Benefits of Exclusive EffectivCRT(TM) and AdaptivCRT(TM) Algorithms, Along with Improved Device Longevity DUBLIN and VIENNA - June 20,...

Data Presented as Late Breaking Clinical Trial at EUROPACE 2017 DUBLIN and VIENNA - June 18, 2017 - Continuing its leadership in the detection, reduction, and treatment of atrial fibrillation...

The MiniMed(TM) 670G System Features the Company's Most Advanced SmartGuard(TM)HCL Technology and New Guardian(TM) Sensor 3 DUBLIN - June 7, 2017 - Medtronic plc (NYSE:MDT), today announced the...

Medtronic Will Host a Webcast of Its Diabetes Group Analyst and Investor Briefingon Saturday, June 10 from 2 - 4 p.m. PDT DUBLIN - June 6, 2017 - Medtronic (NYSE:MDT), the global leader in...

DUBLIN - June 6, 2017 - Medtronic plc (NYSE: MDT) today announced it has received a Health Canada licence for SureTune(TM)3 software for deep brain stimulation (DBS). The latest innovations in the...

DUBLIN - May 31, 2017 - Medtronic plc (NYSE: MDT) recently launched PRODIGY, a 1,650-patient global study, to identify individuals at high risk for opioid induced respiratory depression (OIRD), a...

Q4 Revenue of $7.9 Billion Grew 5% as Reported; 5% at Constant Currency  Q4 GAAP Diluted EPS of $0.84; Q4 Non-GAAP Diluted EPS of $1.33 FY17 Revenue of $29.7 Billion Grew 3% as Reported;...

DUBLIN - May 24, 2017 - Medtronic plc (NYSE: MDT) today announced that the first patient has been enrolled in the IN.PACT(TM) AV Access Drug-Coated Balloon (DCB) study for use in patients with...

DUBLIN - May 24, 2017 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it will participate in the 38th Annual Goldman Sachs Global Healthcare Conference on...

First-Ever Study on 2.0 mm DES, EuroPCR Late-Breaking Data Show Exceptional Deliverability and No Stent Thrombosis for the Resolute Onyx DES DUBLIN and PARIS- May 18, 2017 - Medtronic plc (NYSE:...